1086391-08-3 Usage
General Description
3-bromo-1H-indazol-5-carbaldehyde is a chemical compound with the molecular formula C9H6BrN2O. It is a yellow solid with a molecular weight of 231.06 g/mol. 3-broMo-1H-indazol-5-carbaldehyde is commonly used as a building block in organic synthesis and pharmaceutical research. It is known for its use in the preparation of various heterocyclic compounds and has been studied for potential medicinal applications. Additionally, 3-bromo-1H-indazol-5-carbaldehyde has been investigated for its potential antimicrobial and anticancer properties. It is important to handle this compound with care, as it may be harmful if ingested or inhaled, and can cause skin and eye irritation.
Check Digit Verification of cas no
The CAS Registry Mumber 1086391-08-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,6,3,9 and 1 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1086391-08:
(9*1)+(8*0)+(7*8)+(6*6)+(5*3)+(4*9)+(3*1)+(2*0)+(1*8)=163
163 % 10 = 3
So 1086391-08-3 is a valid CAS Registry Number.
1086391-08-3Relevant articles and documents
ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
Paragraph 1409, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF
-
Page/Page column 62, (2010/09/17)
This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated